Day: March 28, 2024

MCH Group full-year closing 2023: Further consolidation of financial recovery In the business year 2023, MCH Group was able to maintain its operating income at CHF 393.7 million. It posted operating EBITDA of CHF 16.5 million, an improvement of 18% over 2022. However, a negative special effect in the form of a one-off provision places a significant burden on the net result. With the one-off special effect included, the loss for the year is CHF -14.0 million, and the adjusted EBITDA is CHF 12.3 million. Without the negative one-off special effect, the loss for the year amounts to CHF -9.8 million. Thanks to the timely capital increase carried out in autumn 2022, the CHF 100 million bond was repaid in full in May 2023. This increased the equity ratio from 25.5% to 29.4%. The Group was able to further reduce its net debt from CHF 84.6 million...

  Press Release     Paris – March 28, 2024 – EUROAPI today announces that its 2023 Universal Registration Document will be filed with the French Financial Markets Authority (AMF) on April 5, 2024. Financial calendarMay 22, 2024: Annual Shareholder General Meeting Q2 2024: Further information on FOCUS-27 project July 31, 2024 (before market opening): H1 2024 ResultsAbout EUROAPIEUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential...

The supervisory board of AS Tallinna Sadam (hereinafter: Tallinna Sadam) decided to extend the term of office of the member of the management board – CCO Margus Vihman by three years. Margus Vihman’s next term of office starts on 1st November 2024 and lasts until 31st October 2027. The supervisory board also decided to bring the business development function to the management board level and appointed Rene Pärt, the current head of business development, as the fourth member of the management board. Rene Pärt will start his term of office on 1st May 2024, and it lasts until 30th April 2029. Riho Unt, chairman of the supervisory board of Tallinna Sadam, explained that due to the long-term slump in east-west trade, it is essential to pay attention to new business areas and the successful implementation of the port’s growth...

Geneva, Switzerland, March 28, 2024 (GLOBE NEWSWIRE) — This milestone marks a transformative advancement in telecom networks, accommodating billions of new devices and addressing the evolving threat landscape with unparalleled security measures WISeKey International Holding Ltd. (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, operating as a holding company, today announced that it is significantly enhancing telecommunications security in the 5G era through its GSMA Root Certificate Issuer (“GSMA Root CI”) accreditation. This milestone marks a transformative advancement in telecom networks, accommodating billions of new devices and addressing the evolving threat landscape with unparalleled security measures. In an era where telecommunications...

The net asset value (NAV) of EfTEN United Property Fund unit was 10.62 euros at the end of February, increasing by 0.3% over the month. If the fund’s investment in the EfTEN Real Estate Fund AS share is reflected on the basis of its net value, the NAV of EfTEN United Property Fund would be 10.70 euros. In March, the general meeting of shareholders of EfTEN Kinnisvarafond II AS approved the distribution of dividends in the amount of 3.1 million euros and the reduction of the share capital in the amount of 5 million euros. Dividends will be distributed in spring, and the payout related to share capital reduction in autumn, three months after the respective registration in registry. For the EfTEN United Property Fund, this results in a cash flow yield of 5.7% on the investment, which according to the fund terms will be fully distributed...

Successful implementation of Casino Group’s financial restructuring Paris, 28 March 2024 Casino, Guichard-Perrachon (“Casino“) announces the effective completion of its financial restructuring. All the transactions provided for in Casino’s accelerated safeguard plan approved by the Paris Commercial Court on 26 February 2024 (the “Accelerated Safeguard Plan“) and the accelerated safeguard plans of its concerned subsidiaries1 approved by the Paris Commercial Court on 26 February 2024, have been implemented on 27 March 2024. As a result of these transactions, Casino’s share capital is comprised of 37,304,080,735 shares, representing 37,351,145,246 theoretical voting rights. Thus, Mr. Philippe Palazzi acknowledged that the Effective Restructuring Date (as this term is defined in the Accelerated Safeguard...

High Precision System Uses Image Guidance to Target Tumor, Preserve Healthy Tissue & Reduce Risks of Complications such as ED LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) — Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC, located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients. The TRANBERG system is designed to work with multiple image guidance systems for precise and accurate tumor ablation in a minimally invasive, outpatient setting in a urology office or clinic. The system is FDA 510(k) cleared for soft tissue ablation in a urology setting. Operating under CLS’s Mobile Services Agreement, CLS will provide its FDA 510(k)...

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately...